BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26459648)

  • 1. Mifepristone Treatment of Cushing's Syndrome in a Pediatric Patient.
    Banerjee RR; Marina N; Katznelson L; Feldman BJ
    Pediatrics; 2015 Nov; 136(5):e1377-81. PubMed ID: 26459648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Merits and pitfalls of mifepristone in Cushing's syndrome.
    Castinetti F; Fassnacht M; Johanssen S; Terzolo M; Bouchard P; Chanson P; Do Cao C; Morange I; Picó A; Ouzounian S; Young J; Hahner S; Brue T; Allolio B; Conte-Devolx B
    Eur J Endocrinol; 2009 Jun; 160(6):1003-10. PubMed ID: 19289534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome.
    Castinetti F; Brue T; Conte-Devolx B
    Curr Opin Endocrinol Diabetes Obes; 2012 Aug; 19(4):295-9. PubMed ID: 22543346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mifepristone: treatment of Cushing's syndrome.
    Sartor O; Cutler GB
    Clin Obstet Gynecol; 1996 Jun; 39(2):506-10. PubMed ID: 8734015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mifepristone for management of Cushing's syndrome.
    Morgan FH; Laufgraben MJ
    Pharmacotherapy; 2013 Mar; 33(3):319-29. PubMed ID: 23436494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical treatment of Cushing's syndrome: glucocorticoid receptor antagonists and mifepristone.
    Castinetti F; Conte-Devolx B; Brue T
    Neuroendocrinology; 2010; 92 Suppl 1():125-30. PubMed ID: 20829633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with mifepristone.
    Fleseriu M; Molitch ME; Gross C; Schteingart DE; Vaughan TB; Biller BM
    Endocr Pract; 2013; 19(2):313-26. PubMed ID: 23337135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of mifepristone in the treatment of Cushing's syndrome.
    Carroll T; Findling JW
    Drugs Today (Barc); 2012 Aug; 48(8):509-18. PubMed ID: 22916338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mifepristone (RU 486) in Cushing's syndrome.
    Johanssen S; Allolio B
    Eur J Endocrinol; 2007 Nov; 157(5):561-9. PubMed ID: 17984235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.
    Fleseriu M; Biller BM; Findling JW; Molitch ME; Schteingart DE; Gross C;
    J Clin Endocrinol Metab; 2012 Jun; 97(6):2039-49. PubMed ID: 22466348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained weight loss in patients treated with mifepristone for Cushing's syndrome: a follow-up analysis of the SEISMIC study and long-term extension.
    Fein HG; Vaughan TB; Kushner H; Cram D; Nguyen D
    BMC Endocr Disord; 2015 Oct; 15():63. PubMed ID: 26507877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486).
    Chu JW; Matthias DF; Belanoff J; Schatzberg A; Hoffman AR; Feldman D
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3568-73. PubMed ID: 11502780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropsychiatric disorders in Cushing's syndrome.
    Pereira AM; Tiemensma J; Romijn JA
    Neuroendocrinology; 2010; 92 Suppl 1():65-70. PubMed ID: 20829621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in medical therapies for Cushing's syndrome.
    Tritos NA; Biller BM
    Discov Med; 2012 Feb; 13(69):171-9. PubMed ID: 22369976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptomatic Cushing's syndrome and hyperandrogenemia in a steroid cell ovarian neoplasm: a case report.
    Sedhom R; Hu S; Ohri A; Infantino D; Lubitz S
    J Med Case Rep; 2016 Oct; 10(1):278. PubMed ID: 27729065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs in the medical treatment of Cushing's syndrome.
    Schteingart DE
    Expert Opin Emerg Drugs; 2009 Dec; 14(4):661-71. PubMed ID: 19939210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cushing's syndrome: an update on current pharmacotherapy and future directions.
    Creemers SG; Hofland LJ; Lamberts SW; Feelders RA
    Expert Opin Pharmacother; 2015; 16(12):1829-44. PubMed ID: 26133755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global clinical response in Cushing's syndrome patients treated with mifepristone.
    Katznelson L; Loriaux DL; Feldman D; Braunstein GD; Schteingart DE; Gross C
    Clin Endocrinol (Oxf); 2014 Apr; 80(4):562-9. PubMed ID: 24102404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486.
    Nieman LK; Chrousos GP; Kellner C; Spitz IM; Nisula BC; Cutler GB; Merriam GR; Bardin CW; Loriaux DL
    J Clin Endocrinol Metab; 1985 Sep; 61(3):536-40. PubMed ID: 2991327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful long-term treatment of Cushing disease with mifepristone (RU486).
    Basina M; Liu H; Hoffman AR; Feldman D
    Endocr Pract; 2012; 18(5):e114-20. PubMed ID: 22441000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.